Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Chief Commercial Officer | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.37 · Expires 2036-10-05 | Direct | 80,000 |
Reported balance
After 2026-10-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 80,000 · Balance 80,000 F1: 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 21:04 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 80,000 | $0.00 Strike: $9.37 | $0.00 |
DisclosureSEC source: 0001104659-26-114106 · tm2627035-2_4seq1.xml · derivative · entry 1 Rubino Ivana · CIK 0002157418 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2036-10-05 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.